Program
EDG-7500
A development code. Also written as “[14C]-EDG-7500”.
Its studies are mostly in Cardiomyopathy, Hypertrophic, led by Edgewise Therapeutics.
Furthest: phase 2, since Mar 18, 20246 company-led studies, 1 open or runningNext primary completion: Dec 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Edgewise Therapeutics | 61 open or running | phase 2since Mar 18, 2024 | Aug 13, 2023 | Dec 2027phase 2 · NCT06347159 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 13, 2023First study: phase 1 study in Healthy SubjectsFirst studyNCT06011317 · 84 enrolled · United States
- Mar 18, 2024Phase 2 study in Cardiomyopathy, HypertrophicNCT06347159 · 79 enrolled · United States
- Dec 4, 2024Phase 1 study in Healthy VolunteerNCT06738836 · 8 enrolled · United States
- Jun 9, 2025Phase 1 study in Renal ImpairmentsNCT07034768 · 37 enrolled · United States
- Dec 23, 2025Phase 1 study in Hepatic Impairment (HI)NCT07324616 · 25 enrolled · United States
- Mar 3, 2026Phase 1 study in Healthy Adult ParticipantsNCT07456059 · 24 enrolled · United States
Ahead
- Dec 2027Primary completion: phase 2 study in Cardiomyopathy, HypertrophicNCT06347159
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07456059Healthy Adult Participants · United States | 1 | Completed | Jun 1, 2026 | 24 |
| NCT07324616Hepatic Impairment (HI) · United States | 1 | Completed | Apr 7, 2026 | 25 |
| NCT07034768Renal Impairments · United States | 1 | Completed | Dec 22, 2025 | 37 |
| NCT06738836Healthy Volunteer · United States | 1 | Completed | Jan 17, 2025 | 8 |
| NCT06347159Cardiomyopathy, Hypertrophic · United States | 2 | Active, not recruiting | Dec 2027 | 79 |
| NCT06011317Healthy Subjects · United States | 1 | Completed | May 23, 2024 | 84 |
How it is read
Names in the registry
- “EDG-7500”, 6 entries
- “[14C]-EDG-7500”, 1 entry
Codes read as this program: EDG7500.
Conditions, from the studies’ own filings
- Cardiomyopathy, Hypertrophic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.